(Q38019814)

27 August 2017

EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis (English)

1 reference

27 August 2017

1 reference

1 reference

7

Romano Danesi

1 reference

27 August 2017

Francesco Crea

1

1 reference

27 August 2017

Lorenzo Fornaro

2

1 reference

27 August 2017

Guido Bocci

3

1 reference

27 August 2017

Lei Sun

4

1 reference

27 August 2017

William L Farrar

5

1 reference

27 August 2017

Alfredo Falcone

6

1 reference

27 August 2017

language of work or name

1 reference

1 December 2012

1 reference

Cancer and Metastasis Reviews

27 August 2017

1 reference

27 August 2017

31

1 reference

27 August 2017

753-761

1 reference

27 August 2017

3-4

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-012-9387-3

27 August 2017

0 references

cites work

The physics of cancer: the role of physical interactions and mechanical forces in metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Stage II and stage III colon cancer: treatment advances and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Hypoxia and hypoxia-inducible factors: master regulators of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Epigenetic gene regulation in stem cells and correlation to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Epithelial-mesenchymal transitions in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Metastasis: new perspectives on an old problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Anchorage-independent cytokinesis as part of oncogenic transformation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Tumor angiogenesis: molecular pathways and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Cancer stem cells and EMT in carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Cancer stem cells and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Polycomb genes and cancer: time for clinical application?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Clinical significance of Polycomb gene expression in brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

MicroRNAs in the pathogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Coordinated regulation of polycomb group complexes through microRNAs in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Regulation of tumor angiogenesis by EZH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Polycomb repressor complex-2 is a novel target for mesothelioma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

EZH2 is essential for glioblastoma cancer stem cell maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Pharmacokinetics of the antiviral agent 3-deazaneplanocin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

ONCOMINE: a cancer microarray database and integrated data-mining platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Deciphering cellular states of innate tumor drug responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Variation in gene expression patterns in human gastric cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9387-3

10.1007/S10555-012-9387-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference